How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

456 results for

Narcotic Seeking Behavior

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Narcotic Seeking Behavior

Narcotic Seeking Behavior Narcotic Seeking Behavior Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Narcotic Seeking Behavior Narcotic (...) Seeking Behavior Aka: Narcotic Seeking Behavior , Opioid Seeking Behavior , Aberrant Drug-Related Behavior , Pseudo-addiction , Drug Seeking Behavior , Prescription Drug Abuse , Prescription Drug Diversion , Prescription Drug Misuse , Prescription Drug Monitoring Program From Related Chapters II. Epidemiology Prescription Drug Diversion is common Prescription Drug Abusers get their medications from family or friends in over 70% of cases For every 1 death from prescription abuse Treatment admissions

2018 FP Notebook

2. Recruitment to doping and help-seeking behavior of eight female AAS users (PubMed)

Recruitment to doping and help-seeking behavior of eight female AAS users Doping with anabolic androgenic steroids in sports has now developed to a widespread use of these agents among young people outside the sport. This is of major concern to the society. The purpose of the use is mainly for aesthetic reasons and is seen as a male phenomenon. But use also occurs in women where the knowledge is scarce. Our aim was to identify the pattern of doping agents in eight female cases and compare them (...) with similar data from men.Eight female users were recruited through Anti-Doping Hot-Line, a national telephone counseling service on doping issues during the years 1998-2004. The use was confirmed with urine doping analysis at the Doping Laboratory. The characteristic of use, co-use of narcotics/other doping agents, exercise pattern, adverse-side effects, family history and reason to begin was evaluated.The women used on average 1.9 different anabolic androgenic steroids and clenbuterol preparations

Full Text available with Trip Pro

2016 Substance abuse treatment, prevention, and policy

3. Narcotic Seeking Behavior

Narcotic Seeking Behavior Narcotic Seeking Behavior Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Narcotic Seeking Behavior Narcotic (...) Seeking Behavior Aka: Narcotic Seeking Behavior , Opioid Seeking Behavior , Aberrant Drug-Related Behavior , Pseudo-addiction , Drug Seeking Behavior , Prescription Drug Abuse , Prescription Drug Diversion , Prescription Drug Misuse , Prescription Drug Monitoring Program From Related Chapters II. Epidemiology Prescription Drug Diversion is common Prescription Drug Abusers get their medications from family or friends in over 70% of cases For every 1 death from prescription abuse Treatment admissions

2015 FP Notebook

4. Treatment Outcomes Among Patients With Prescription Narcotic Drug Use Disorder

Criteria: Patients seeking treatment for prescription narcotic drug use disorder (ICD-10: F111, F112, F131, and F132) ≥ 18 years Willing to participate and who have provided written informed consent. Exclusion Criteria: Inability to understand spoken and written study information. Having started tapering prior to the start of the study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff (...) provided by Johan Franck, Karolinska Institutet: behavior, addictive addiction medicine substance-related disorders abuse, narcotic addiction, narcotic analgesics, narcotic opioid-related disorders benzodiazepines prescription drugs Additional relevant MeSH terms: Layout table for MeSH terms Disease Substance-Related Disorders Pathologic Processes Chemically-Induced Disorders Mental Disorders Narcotics Central Nervous System Depressants Physiological Effects of Drugs Analgesics Sensory System Agents

2018 Clinical Trials

5. Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review

, adolescents are more prone to impulsive behaviors, risk taking, and drug and reward seeking compared to adults—all of which are behaviors that are linked to substance use (Chambers et al., 2003; Simon & Moghaddam, 2015). Indeed, animal studies of neural processing have demonstrated that adolescent and adult brains respond differently to rewards, with activity in adolescents’ brain regions of learning and habit formation potentially predisposing them to form problematic substance use habits (Sturman (...) Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review A Campbell Systematic Review 2018:9 Education Coordinating Group Emily A. Hennessy, Emily E. Tanner-Smith, Andrew J. Finch, Nila Sathe, Shannon Kugley Recovery schools for improving behavioral and academic outcomes among students in recovery from substance use disorders: a systematic review Published: October 2018 Search executed: September 2018The

2018 Campbell Collaboration

6. Narcotic Use and Postoperative Doctor Shopping Among Patients with Nephrolithiasis Requiring Operative Intervention: Implications for Patient Safety. (PubMed)

institution from January to December 2013. Using the Tennessee CSMD (Controlled Substances Medication Database) patients were categorized by the number of postoperative narcotic providers. Doctor shopping behavior was identified as any patient seeking more than 1 narcotic provider within 3 months of surgery. Demographic and clinical characteristics associated with doctor shopping behavior were identified.During the study period 200 eligible patients underwent ureteroscopy with laser lithotripsy (...) Narcotic Use and Postoperative Doctor Shopping Among Patients with Nephrolithiasis Requiring Operative Intervention: Implications for Patient Safety. We sought to determine perioperative patterns of narcotic use and the prevalence of postoperative doctor shopping among patients with nephrolithiasis requiring operative management.We retrospectively reviewed the records of consecutive patients residing in Tennessee who required ureteroscopy with laser lithotripsy for nephrolithiasis at a single

2016 Journal of Urology

7. Take-home methadone: contingency effects on drug-seeking and productivity of narcotic addicts. (PubMed)

Take-home methadone: contingency effects on drug-seeking and productivity of narcotic addicts. 735908 1979 03 24 2018 04 18 0306-4603 3 3-4 1978 Addictive behaviors Addict Behav Take-home methadone: contingency effects on drug-seeking and productivity of narcotic addicts. 215-20 Milby J B JB Garrett C C English C C Fritschi O O Clarke C C eng Clinical Trial Journal Article Randomized Controlled Trial England Addict Behav 7603486 0306-4603 0 Pharmaceutical Preparations UC6VBE7V1Z Methadone IM (...) Adult Behavior Efficiency Female Humans Male Methadone administration & dosage therapeutic use Middle Aged Pharmaceutical Preparations urine Self Administration Substance-Related Disorders psychology rehabilitation 1978 1 1 1978 1 1 0 1 1978 1 1 0 0 ppublish 735908 0306-4603(78)90022-9

1979 Addictive behaviors

8. Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction

Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02801357 Recruitment Status : Completed First

2016 Clinical Trials

9. Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects

Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Studies (...) of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects (YHO) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01536925 Recruitment Status : Completed First Posted : February 22, 2012 Last Update Posted : April 5, 2018 Sponsor: Wayne State University Collaborator: National Institute on Drug Abuse

2012 Clinical Trials

10. Neural Basis of Eating Behavior in Abstinent Smokers

quit attempt in the next 1-2 months (treatment-seeking), because our prior work suggests that motivated subjects are more sensitive to medication effects on smoking behavior. Using a scale from 0 to 100 (100, being extremely interested), subjects must rate their interest in quitting smoking within the next 1-2 months greater than 50. Able to communicate fluently in English (i.e. speaking, writing, and reading). Exclusion Criteria Subjects who present and/or self-report with the following criteria (...) Neural Basis of Eating Behavior in Abstinent Smokers Neural Basis of Eating Behavior in Abstinent Smokers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Neural Basis of Eating Behavior in Abstinent Smokers

2018 Clinical Trials

11. Quantifying Drug-seeking Behavior: A Case Control Study. (PubMed)

pain.The odds ratios for each studied behavior being used by drug seeking patients as compared to controls were: non-narcotic allergy: 3.4, medication by name: 26.3, medication refill: 19.2, lost or stolen medication: 14.1, three or more pain related visits in different parts of the body: 29.3, 10 out of 10 pain: 13.9, three visits in 7 days: 30.8, out of medication: 26.9, headache: 10.9, back pain: 13.6, and dental pain: 6.3. Zero patients in the control group complained of greater than 10-out-of-10 (...) Quantifying Drug-seeking Behavior: A Case Control Study. Drug-seeking behavior (DSB) is common in the Emergency Department (ED), yet the literature describing DSB in the ED consists predominantly of anecdotal evidence.To perform a case-control study examining the relative frequency of DSB in suspected drug-seeking patients as compared to all ED patients.We performed a retrospective chart review of 152 drug-seeking patients and of age- and gender-matched controls, noting which of the following

2011 Journal of Emergency Medicine

12. Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02510014 Recruitment Status : Completed First Posted : July 28, 2015 Results First

2015 Clinical Trials

13. Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02357901 Recruitment Status : Completed First Posted

2015 Clinical Trials

14. Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol (PubMed)

Differential behavioral and molecular alterations upon protracted abstinence from cocaine versus morphine, nicotine, THC and alcohol Unified theories of addiction are challenged by differing drug-seeking behaviors and neurobiological adaptations across drug classes, particularly for narcotics and psychostimulants. We previously showed that protracted abstinence to opiates leads to despair behavior and social withdrawal in mice, and we identified a transcriptional signature in the extended (...) amygdala that was also present in animals abstinent from nicotine, Δ9-tetrahydrocannabinol (THC) and alcohol. Here we examined whether protracted abstinence to these four drugs would also share common behavioral features, and eventually differ from abstinence to the prototypic psychostimulant cocaine. We found similar reduced social recognition, increased motor stereotypies and increased anxiety with relevant c-fos response alterations in morphine, nicotine, THC and alcohol abstinent mice. Protracted

Full Text available with Trip Pro

2016 Addiction biology

15. Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain

smoking and gain less weight. Condition or disease Intervention/treatment Phase Smoking Cessation Weight Loss Behavioral: BAS+ Behavioral: SC Not Applicable Detailed Description: This is a randomized clinical trial of the efficacy of a behavioral activation intervention to smoking cessation and to post-cessation weight gain (BAS+) plus transdermal nicotine (TN) compared to standard smoking cessation counseling (SC) plus TN in treatment-seeking smokers. After completing an Intake Visit (~week -3 (...) Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2016 Clinical Trials

16. Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers

Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Ghrelin for Alcohol Use in Non (...) -Treatment-Seeking Heavy Drinkers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01779024 Recruitment Status : Completed First Posted : January 29, 2013 Results First Posted : August 3, 2018 Last Update Posted : August 3, 2018 Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA

2013 Clinical Trials

17. Naltrexone and Memantine Effects on Alcohol Drinking Behaviors

table for MeSH terms Alcohol Drinking Drinking Behavior Ethanol Naltrexone Memantine Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs Alcohol Deterrents Narcotic Antagonists Sensory System Agents Peripheral Nervous System Agents Antiparkinson Agents Anti-Dyskinesia Agents Dopamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents (...) Naltrexone and Memantine Effects on Alcohol Drinking Behaviors Naltrexone and Memantine Effects on Alcohol Drinking Behaviors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Naltrexone and Memantine Effects

2012 Clinical Trials

18. Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors

Additional relevant MeSH terms: Layout table for MeSH terms Alcohol Drinking Drinking Behavior Ethanol Naltrexone Anti-Infective Agents, Local Anti-Infective Agents Central Nervous System Depressants Physiological Effects of Drugs Alcohol Deterrents Narcotic Antagonists Sensory System Agents Peripheral Nervous System Agents (...) Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Kappa-PET Imaging and Naltrexone

2012 Clinical Trials

19. Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence

, with no placebo control. Then, there will be a twelve-week, double-blind, placebo-controlled study in male and female subjects seeking treatment for cannabis dependence (n=40). All participants will receive a combination of pharmacotherapy (Sativex Spray or Placebo Spray) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy (MET/CBT). The subjects will have to come daily to the centre to assess usage of medication. Following the medication phase (...) Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Sativex

2012 Clinical Trials

20. Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia

Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Naltrexone and Behavioral Drug and HIV Risk Reduction Counseling in Russia The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01389167 Recruitment Status : Completed First Posted : July 7, 2011 Last Update Posted : January 11, 2018 Sponsor: Yale University Collaborators: St. Petersburg State Pavlov Medical

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>